Published in Blood on June 15, 1999
Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev (2003) 2.90
Discovery of a viral NLR homolog that inhibits the inflammasome. Science (2011) 2.36
Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol (2001) 2.20
Differential regulation of the overlapping Kaposi's sarcoma-associated herpesvirus vGCR (orf74) and LANA (orf73) promoters. J Virol (2001) 1.84
Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia? J Exp Med (2000) 1.52
Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology (2007) 1.38
KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: persistence of infection during hematopoiesis in vitro and in vivo. Blood (2006) 1.37
KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J Clin Invest (2006) 1.29
Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol (2000) 1.29
The role of macrophage polarization in infectious and inflammatory diseases. Mol Cells (2014) 1.28
Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome. Front Microbiol (2012) 1.25
An Sp1 response element in the Kaposi's sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle induction by butyrate. J Virol (2005) 1.19
Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin Microbiol Rev (2002) 1.12
Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood (2006) 1.08
beta-Adrenoreceptors reactivate Kaposi's sarcoma-associated herpesvirus lytic replication via PKA-dependent control of viral RTA. J Virol (2005) 1.08
Effective human herpesvirus 8 infection of human umbilical vein endothelial cells by cell-mediated transmission. J Virol (2001) 1.03
Activation of plasmacytoid dendritic cells by Kaposi's sarcoma-associated herpesvirus. J Virol (2010) 1.03
Active lytic infection of human primary tonsillar B cells by KSHV and its noncytolytic control by activated CD4+ T cells. J Clin Invest (2011) 1.02
Transcription pattern of human herpesvirus 8 open reading frame K3 in primary effusion lymphoma and Kaposi's sarcoma. J Virol (2001) 1.02
KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathog (2009) 1.01
Gene expression profile of AIDS-related Kaposi's sarcoma. BMC Cancer (2003) 1.01
Human herpesvirus 8--a novel human pathogen. Virol J (2005) 1.00
Tissue specificity of the Kaposi's sarcoma-associated herpesvirus latent nuclear antigen (LANA/orf73) promoter in transgenic mice. J Virol (2002) 0.98
Extracellular Hsp90 serves as a co-factor for NF-κB activation and cellular pathogenesis induced by an oncogenic herpesvirus. Am J Cancer Res (2011) 0.98
Monocytes as regulators of inflammation and HIV-related comorbidities during cART. J Immunol Res (2014) 0.98
Susceptibility of human fetal mesenchymal stem cells to Kaposi sarcoma-associated herpesvirus. Blood (2004) 0.95
Latent Kaposi's sarcoma-associated herpesvirus infection of monocytes downregulates expression of adaptive immune response costimulatory receptors and proinflammatory cytokines. J Virol (2012) 0.95
The viral interferon regulatory factors of KSHV: immunosuppressors or oncogenes? Front Immunol (2011) 0.94
Kaposi's sarcoma-associated herpesvirus virions inhibit interferon responses induced by envelope glycoprotein gpK8.1. J Virol (2006) 0.93
Human Herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during the course of asymptomatic infection and Kaposi sarcoma. PLoS Pathog (2012) 0.93
A replication-defective gammaherpesvirus efficiently establishes long-term latency in macrophages but not in B cells in vivo. J Virol (2008) 0.91
Peripheral blood endothelial progenitors as potential reservoirs of Kaposi's sarcoma-associated herpesvirus. PLoS One (2008) 0.90
Activation of human herpesvirus replication by apoptosis. J Virol (2013) 0.90
An important role for mitochondrial antiviral signaling protein in the Kaposi's sarcoma-associated herpesvirus life cycle. J Virol (2014) 0.90
Human herpesvirus 8 (HHV-8) detected in two patients with Kaposi's sarcoma-like pyogenic granuloma. J Clin Pathol (2002) 0.88
Viral interferon regulatory factors decrease the induction of type I and type II interferon during rhesus macaque rhadinovirus infection. J Virol (2011) 0.87
Kaposi's sarcoma-associated herpesvirus and innate immunity. Future Virol (2010) 0.85
Professional antigen presenting cells in human herpesvirus 8 infection. Front Immunol (2013) 0.84
CD4+ and CD8+ T-cell skewness in classic Kaposi sarcoma. Neoplasia (2012) 0.83
Human herpesvirus-8 infection of primary pulmonary microvascular endothelial cells. Am J Respir Cell Mol Biol (2008) 0.83
The phosphatase Shp2 is required for signaling by the Kaposi's sarcoma-associated herpesvirus viral GPCR in primary endothelial cells. Virology (2009) 0.82
The MARCH family E3 ubiquitin ligase K5 alters monocyte metabolism and proliferation through receptor tyrosine kinase modulation. PLoS Pathog (2011) 0.82
Amplification of autoimmune disease by infection. Arthritis Res Ther (2005) 0.81
Human herpesvirus-8 infection leads to expansion of the preimmune/natural effector B cell compartment. PLoS One (2010) 0.81
Oncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic Replication. PLoS Pathog (2016) 0.79
The Kynurenine Pathway of Tryptophan Catabolism and AIDS-Associated Kaposi Sarcoma in Africa. J Acquir Immune Defic Syndr (2015) 0.79
Kaposi's sarcoma-associated herpesvirus-encoded LANA down-regulates IL-22R1 expression through a cis-acting element within the promoter region. PLoS One (2011) 0.77
Kaposi sarcoma herpesvirus pathogenesis. Philos Trans R Soc Lond B Biol Sci (2017) 0.76
Regulation of Wnt/β-catenin signaling by herpesviruses. World J Virol (2016) 0.75
Immune Reconstitution Inflammatory Syndrome in HIV infection: taking the bad with the good. Oral Dis (2016) 0.75
Human herpes virus 8 replication during disseminated tuberculosis in a man with human immunodeficiency virus: a case report. J Med Case Rep (2009) 0.75
Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes. MBio (2017) 0.75
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell (1986) 12.74
Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature (1977) 12.57
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science (1984) 11.30
Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1982) 11.15
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell (1986) 10.70
Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science (1984) 10.40
Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A (1978) 9.59
The trans-activator gene of HTLV-III is essential for virus replication. Nature (1986) 8.65
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A (1988) 8.40
A molecular clone of HTLV-III with biological activity. Nature (1985) 8.30
Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci U S A (1986) 8.06
Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses (1987) 7.85
Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science (1986) 7.81
Onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. Nature (1982) 6.78
Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science (1986) 6.53
Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science (1985) 6.51
Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science (1985) 6.48
Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science (1992) 6.35
Functional and morphologic characterization of human T cells continuously grown in vitro. J Immunol (1977) 6.30
Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J Virol (1987) 6.20
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science (1986) 5.86
Expression of cellular homologues of retroviral onc genes in human hematopoietic cells. Proc Natl Acad Sci U S A (1982) 5.80
Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol (1985) 5.70
Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet (1994) 5.49
The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med (1996) 5.46
Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science (1984) 5.43
Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science (1985) 5.42
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Genomic diversity of human T-lymphotropic virus type III (HTLV-III). Science (1985) 5.33
A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science (1982) 5.30
Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature (1982) 5.11
Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc Natl Acad Sci U S A (1985) 5.10
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature (1985) 5.10
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Human T-lymphotropic retroviruses. Nature (1985) 5.04
Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Natl Acad Sci U S A (1980) 4.91
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA (1999) 4.91
Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A (1984) 4.90
Nucleotide sequence of cloned cDNA of human c-myc oncogene. Nature (1983) 4.83
Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science (1983) 4.72
Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29). Proc Natl Acad Sci U S A (1982) 4.70
Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A (1986) 4.68
Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology (1981) 4.68
Isolation and transmission of human retrovirus (human t-cell leukemia virus). Science (1983) 4.67
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (1990) 4.47
Seroepidemiology of HTLV-III antibody in Danish homosexual men: prevalence, transmission, and disease outcome. Br Med J (Clin Res Ed) (1984) 4.39
Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. Nature (1981) 4.38
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A (1995) 4.37
Differential expression of the amv gene in human hematopoietic cells. Proc Natl Acad Sci U S A (1982) 4.37
Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature (1984) 4.35
Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses. Nature (1987) 4.35
Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus. Science (1985) 4.31
Molecular targets for AIDS therapy. Science (1990) 4.28
Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science (1990) 4.28
Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA (1985) 4.26
Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes. Proc Natl Acad Sci U S A (1981) 4.24
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. Virology (1983) 4.11
Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24. J Virol (1988) 4.06
Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol (1992) 3.93
Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr (2001) 3.83
Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science (1983) 3.82
Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J (2010) 3.81
Biologically diverse molecular variants within a single HIV-1 isolate. Nature (1988) 3.80
Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet (1984) 3.77
Chromosomal sublocalization of human c-myb and c-fes cellular onc genes. Nature (1983) 3.77
Natural antibodies to the structural core protein (p24) of the human T-cell leukemia (lymphoma) retrovirus found in sera of leukemia patients in Japan. Proc Natl Acad Sci U S A (1982) 3.75
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol (1993) 3.68
Adult T-cell lymphoma-leukaemia in Blacks from the West Indies. Lancet (1982) 3.67
Human T lymphotropic virus type III infection of human alveolar macrophages. Blood (1986) 3.66
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. Science (1984) 3.50
HTLV-III in cells cultured from semen of two patients with AIDS. Science (1984) 3.47
Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol (1981) 3.46
Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A (1993) 3.45
A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med (1984) 3.41
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol (1990) 3.35
Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med (1981) 3.30
The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med (1996) 3.30
DNA-dependent DNA polymerases I and II from normal human-blood lymphocytes. Proc Natl Acad Sci U S A (1972) 3.27
Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ (2007) 3.22
Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene. Science (1984) 3.20
Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature (1986) 3.19
LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J (2009) 3.16